A5072464118- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Retinoids in leukemia and cellular processes
- Acute Lymphoblastic Leukemia research
- Sarcoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Histone Deacetylase Inhibitors Research
- RNA Interference and Gene Delivery
- Lymphoma Diagnosis and Treatment
- Blood disorders and treatments
- Hematopoietic Stem Cell Transplantation
- Cancer therapeutics and mechanisms
- Cutaneous lymphoproliferative disorders research
- Cancer Genomics and Diagnostics
- Neutropenia and Cancer Infections
- Viral-associated cancers and disorders
- Hematological disorders and diagnostics
- Immune cells in cancer
- CNS Lymphoma Diagnosis and Treatment
- Soft tissue tumor case studies
- Advanced biosensing and bioanalysis techniques
- Mast cells and histamine
University of Colorado Anschutz Medical Campus
2014-2024
University of Colorado Denver
2015-2024
University of Colorado Hospital
2013-2023
University of Denver
2015
Johns Hopkins University
2007-2008
Venetoclax-based therapy can induce responses in approximately 70% of older previously untreated patients with acute myeloid leukemia (AML). However, up-front resistance as well relapse following initial response demonstrates the need for a deeper understanding mechanisms. In present study, we report that to venetoclax +azacitidine AML correlate closely developmental stage, where phenotypically primitive is sensitive, but monocytic more resistant. Mechanistically, resistant has distinct...
Venetoclax (ven) plus azacitidine (aza) is the standard of care for patients with newly diagnosed acute myeloid leukemia (AML) who are not candidates intensive chemotherapy (IC). Some IC instead receive ven/aza. We retrospectively analyzed AML received ven/aza (n = 143) or 149) to compare outcomes, seek variables that could predict response 1 therapy other, and ascertain whether treatment recommendations be refined. The rates were 76.9% 70.5% IC. median overall survival (OS) was 884 days...
Abstract The BCL2 inhibitor venetoclax has recently emerged as an important component of acute myeloid leukemia (AML) therapy. Notably, use this agent revealed a previously unrecognized form pathogenesis characterized by monocytic disease progression. We demonstrate that arises from fundamentally different type stem cell (LSC), which we designate LSC (m-LSC), is developmentally and clinically distinct the more well-described primitive (p-LSC). m-LSC distinguished unique immunophenotype...
Key Points Responses and survival with venetoclax for “real-world” AML patients were promising but inferior to those treated in a clinical trial. Compared induction, response rates are as high would be predicted had lower than expected early death rate.
Venetoclax+azacitidine is the standard of care for newly-diagnosed patients with acute myeloid leukemia (AML) whom intensive chemotherapy inappropriate. Efforts to optimize this regimen are necessary. We designed a clinical trial investigate two hypotheses: i) higher doses venetoclax tolerable and more effective, ii) azacitidine can be discontinued after deep remissions. Forty-two newly diagnosed AML were enrolled in investigator-initiated High Dose Discontinuation Azacitidine+Venetoclax...
A rare but well-known association between plasma cell neoplasms and neutrophilia is known to exist. Whether the secondary neoplasm or this convergence represents two independent clonal disorders unclear. We reviewed five consecutive cases from a single institution over 3-year period, applying molecular, cytogenetic cytokine-profiling approaches determine whether associated with reactive process. report, for first time, occurrence of SETBP1 mutation in cases, as well changes G-CSF IL-6 wild...
Rectal tissue is often seen in needle biopsies of the prostate gland. On rare occasion distorted rectal glands can mimic prostatic adenocarcinoma, an issue not previously addressed peer-reviewed literature. We evaluated 16 received consultation where submitting pathologist questioned whether a focus was cancer. In addition to architecture, features mimicking cancer included: (1) blue-tinged intraluminal mucinous secretions 10 cases (63%), (2) prominent nucleoli 6 (37%), (3) mitotic activity...
Predictors for response to intensive therapy in AML have focused on baseline factors: percent leukemic blasts marrow, cytogenetic/molecular genetic abnormalities, and presence of secondary AML. Non-baseline dynamic factors, occurring after induction but before response, may be useful decisions related salvage chemotherapy. We hypothesized white blood cell (WBC) count nadir a real time indicator treatment efficacy. also examined whether stem transplant (SCT) or molecular abnormalities are...
The Castleman triad has been described in a select few patients presenting with retroperitoneal mass, mucocutaneous pemphigus vulgaris, and bronchiolitis obliterans. Here, we describe the 19-year-old male unicentric hyaline vascular type disease (HV-CD). This patient presented an array of positive antibodies, including anti-cyclic citrullinated peptide, anti-double-stranded DNA, Sjogren's IgG. Interestingly, patient's rheumatologic symptoms resolved after tumor resection, while his antibody...
Acute lymphoblastic leukemia (ALL) in infants <1-year-old is biologically different from ALL older children. Although KMT2A rearrangement the predominant genetic signature infantile B-ALL, disease course heterogenous, behaving more aggressively younger infants. We investigated clinicopathological differences throughout first year to understand transition pediatric B-ALL. In a multi-institutional review involving four medical institutions, 54 cases of B-ALL were identified. Patients divided...
Widely-used response criteria, conditional upon count recovery, were developed for acute myeloid leukemia (AML) in the context of intensive chemotherapy (IC). Extending these definitions to continuously-administered venetoclax-based therapies might underestimate responses. Best practices mandate interruption after an end-of-cycle 1 bone marrow biopsy shows morphologic remission with cytopenias. We analyzed 435 patients newly-diagnosed AML and follow-up assessments. Of 101 who responded...
Case: This report describes a sixty-one-year old man who was diagnosed with myxoid liposarcoma of the left thigh that resected and then treated radiation therapy. He underwent yearly surveillance imaging but presented seventeen years after initial resection symptoms heart failure. found to have cardiac abnormality first thought be pseudoaneurysm later shown liposarcoma, presumably metastatic. Conclusion: Myxoid can present late metastasis, including heart.
Introduction: Myxoid soft tissue tumors represent a heterogenous group of neoplasms. The study presented our experience on cytopathology myxoid fine needle aspiration (FNA) and aimed to apply the recently proposed WHO system for reporting cytopathology. Material Methods: We performed 20-year retrospective search archives identify all FNAs lesions. All cases were reviewed, was applied. Results: 129 in 121 patients (62 males; 59 females) showed prominent component, accounting 2.4% FNAs. 111...